Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00502775 · ClinicalTrials.gov registry record · Phase 4
Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 680
- Enrollment target
NCT00502775 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 680 participants.
The verdict
NCT00502775, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 680 participants
- Enrollment target
Study Summary
The primary objective of the study is to compare nighttime symptom relief of fluticasone furoate nasal spray versus oral fexofenadine
Interventions
- DRUG fluticasone furoate, fexofenadine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 680 participants |
| Start Date | 2007-08 |
| Est. Completion | 2007-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00502775
The ClinicalTrials.gov registry entry for NCT00502775 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 680 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which fluticasone furoate, fexofenadine is the first listed.
NCT00502775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00502775 about?
NCT00502775 is a clinical study titled "Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine". The primary objective of the study is to compare nighttime symptom relief of fluticasone furoate nasal spray versus oral fexofenadine
What is the current status of trial NCT00502775?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 680 participants. The study started on 2007-08. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00502775?
The interventions under investigation include: fluticasone furoate, fexofenadine (DRUG).
Who is sponsoring clinical trial NCT00502775?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.